Journal For Immunotherapy Of Cancer

Journal For Immunotherapy Of Cancer

癌症免疫治疗杂志

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Journal For Immunotherapy Of Cancer》是由BioMed Central出版社于2013年创办的英文国际期刊(ISSN: 2051-1426,E-ISSN: 2051-1426),该期刊长期致力于免疫学领域的创新研究,主要研究方向为Biochemistry, Genetics and Molecular Biology-Molecular Medicine。作为SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA开放获取模式(OA占比1%),以发表免疫学领域等方向的原创性研究为核心(研究类文章占比93.76%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在417篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Journal For Immunotherapy Of Cancer审稿周期约为 18 Weeks 。该刊近年未被列入国际预警名单,年发文量约417篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 417 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
1区
IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
1区 2区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
2区 2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 12 / 181

93.6%

学科:ONCOLOGY SCIE Q1 26 / 322

92.1%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 14 / 181

92.54%

学科:ONCOLOGY SCIE Q1 29 / 322

91.15%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:17.7 SJR:3.728 SNIP:1.645
学科类别 分区 排名 百分位
大类:Pharmacology, Toxicology and Pharmaceutics 小类:Pharmacology Q1 11 / 313

96%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Molecular Medicine Q1 11 / 178

94%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Oncology Q1 25 / 404

93%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Cancer Research Q1 18 / 230

92%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Immunology and Allergy Q1 20 / 233

91%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Immunology Q1 23 / 236

90%

期刊发文

  • Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation

    Author: Zhang, Biying; Li, Jiao; Hua, Qingling; Wang, Haihong; Xu, Guojie; Chen, Jiayuan; Zhu, Ying; Li, Ruiqi; Liang, Qing; Wang, Lanqing; Jin, Min; Tang, Jing; Lin, Zhenyu; Zhao, Lei; Zhang, Dejun; Yu, Dandan; Ren, Jinghua; Zhang, Tao

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005592

  • Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy

    Author: Tang, Rui; He, Hongye; Lin, Xiaohong; Wu, Nianhong; Wan, Li; Chen, Qiaoqi; Hu, Yaqin; Cheng, Chen; Cao, Yuting; Guo, Xun; Zhou, Ying; Xiong, Xialin; Zheng, Min; Wang, Qi; Li, Faqi; Zhou, Yang; Li, Pan

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-006226

  • Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy

    Author: Shi, Lin; Lu, Jinying; Zhong, Da; Song, Meijuan; Liu, Jian; You, Wenhua; Li, Wen-Hui; Lin, Lin; Shi, Dongyan; Chen, Yun

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005902

  • STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

    Author: Ding, Liya; Wang, Qiwei; Martincuks, Antons; Kearns, Michael J.; Jiang, Tao; Lin, Ziying; Cheng, Xin; Qian, Changli; Xie, Shaozhen; Kim, Hye-Jung; Launonen, Inga-Maria; Faerkkilae, Anniina; Roberts, Thomas M.; Freeman, Gordon J.; Liu, Joyce F.; Konstantinopoulos, Panagiotis A.; Matulonis, Ursula; Yu, Hua; Zhao, Jean J.

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005627

  • Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy

    Author: Dai, Jie; Bai, Xue; Gao, Xuan; Tang, Lirui; Chen, Yu; Sun, Linzi; Wei, Xiaoting; Li, Caili; Qi, Zhonghui; Kong, Yan; Cui, Chuanliang; Chi, Zhihong; Sheng, Xinan; Xu, Zelong; Lian, Bin; Li, Siming; Yan, Xieqiao; Tang, Bixia; Zhou, Li; Wang, Xuan; Xia, Xuefeng; Guo, Jun; Mao, Lili; Si, Lu

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005937

  • New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

    Author: Bamias, Aristotelis; Merseburger, Axel; Loriot, Yohann; James, Nicholas; Choy, Ernest; Castellano, Daniel; Lopez-Rios, F.; Calabro, Fabio; Kramer, Mario; de Velasco, Guillermo; Zakopoulou, Roubini; Tzannis, Kimon; Sternberg, Cora N.

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2022-005977

  • Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers

    Author: Ba, Hongping; Dai, Zigang; Zhang, Zunyue; Zhang, Peng; Yin, Bingjiao; Wang, Jing; Li, Zhuoya; Zhou, Xiaoxi

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 1, pp. -. DOI: 10.1136/jitc-2021-003837

  • Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases

    Author: Zhang, Chong; Wang, Xiang-Yu; Zuo, Jie-Liang; Wang, Xue-Fu; Feng, Xiao-Wen; Zhang, Bo; Li, Yi-Tong; Yi, Chen-He; Zhang, Peng; Ma, Xiao-Chen; Chen, Zhen-Mei; Ma, Yue; Han, Jia-Hao; Tao, Bao-Rui; Zhang, Rui; Wang, Tian-Qi; Tong, Li; Gu, Wang; Wang, Si-Yu; Zheng, Xiao-Fei; Yuan, Wen-Kang; Kan, Zi-Jie; Fan, Jie; Hu, Xiang-Yang; Li, Jun; Zhang, Chao; Chen, Jin-Hong

    Journal: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023; Vol. 11, Issue 2, pp. -. DOI: 10.1136/jitc-2022-006425